Comprehensive Review Maps CGRP Biology, Signaling, and Therapeutic Landscape Across Migraine, Pain, and Cancer
Background
The calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, is a critical pleiotropic signaling molecule widely distributed in the nervous system. Its involvement in diverse physiological functions, including vasodilation, nociception, and neurogenic inflammation, makes it a significant target for therapeutic intervention. Historically, migraine treatment has faced challenges with efficacy and side effects, prompting a search for more targeted mechanisms. CGRP's central role in migraine pathophysiology has driven the development of novel therapies, addressing a key gap in managing this debilitating condition and other pain disorders.
Study Design
This narrative review synthesized current knowledge on the CGRP system. Researchers integrated recent advances in its molecular structure, gene organization, and post-translational processing, alongside high-resolution structural insights into its heterodimeric receptor complex (CLR-RAMP1) obtained via cryo-electron microscopy. The review also included long-term safety data on anti-CGRP monoclonal antibodies and discussed emerging cardiovascular risk signals. Intracellular signaling cascades, such as the canonical cAMP-PKA pathway, MAP kinase activation, and context-dependent calcium signaling, were examined in relation to CGRP's diverse physiological functions.
Results
The review highlighted CGRP's pleiotropic roles in vasodilation, nociception modulation, neurogenic inflammation, gastrointestinal motility, bone metabolism, tissue regeneration, and energy homeostasis. It detailed the central role of CGRP in migraine pathophysiology, leading to the development of targeted therapies.
The pharmacological landscape includes three generations of small-molecule CGRP receptor antagonists (gepants) and four approved monoclonal antibodies targeting CGRP or its receptor. These therapies demonstrate varying efficacy and safety profiles, with the review providing a comparative analysis for clinical positioning. Beyond migraine, emerging preclinical roles for the CGRP system were discussed in chronic pain, osteoarthritis, cardiovascular diseases, sepsis, cancer (specifically bone metastases and tumor microenvironment immunomodulation), and neurodegenerative disorders like Alzheimer's.
Key Findings
- CGRP is a pleiotropic neuropeptide involved in vasodilation, nociception, neurogenic inflammation, and energy homeostasis.
- High-resolution structural insights into the
CLR-RAMP1receptor complex are now available viacryo-electron microscopy. - The pharmacological landscape includes three generations of gepants and four approved anti-CGRP monoclonal antibodies.
- CGRP signaling involves canonical
cAMP-PKApathway,MAP kinaseactivation, and context-dependentcalcium signaling. - Emerging preclinical roles for CGRP include chronic pain, osteoarthritis, cardiovascular disease, sepsis, and cancer.
Why It Matters
This comprehensive review provides a critical update for clinicians and researchers on the expanding therapeutic potential of targeting the CGRP system. Understanding CGRP's diverse physiological roles and the mechanisms of current therapies (gepants and monoclonal antibodies) can inform more precise treatment strategies for migraine and other CGRP-mediated conditions. The discussion of emerging roles in chronic pain, cardiovascular disease, and cancer opens new avenues for drug development, potentially expanding the utility of CGRP-modulating agents beyond their current indications. This synthesis helps bridge the gap between basic science and clinical application, guiding future research and personalized medicine approaches.
cgrp
migraine
gepants
monoclonal-antibodies
chronic-pain
cancer